In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, including AirSense 10 and ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.

From those humble beginnings, it now seems that a new bag-loving predecessor has emerged in 2025: Timothée Chalamet and his love for teeny tiny accessories. Whispery mustache included ...

Learn More ResMed Inc. (ASX: RMD ... The R&D product launch cadence has stepped up with innovative mask and accessories launches over 2HCY24. Our revenue growth estimates for masks are 2.4% ...

ResMed Inc. (ASX: RMD) shares have been on fire over the past 12 months. During this time, the sleep disorder treatment company's shares have rallied 44% higher. But if you thought the gains were ...

Below we've gathered all of the Switch accessories we've tested and deemed worthy of any Switch user in 2025 and beyond. The small thumbsticks and triggers available on Nintendo Switch's Joy-Con ...